Abstract:The incorporation of aggregation‐induced emission luminogen (AIEgen) into porous prussian blue (PB) nanocatalyzer significantly boosts fluorescence brightness and photodynamic therapy attributes as the molecular motion of AIEgen is highly restricted. PB can catalyze tumor‐overexpressed H2O2 to generate oxygen to amplify photodynamic efficacy, and the near‐infrared absorption also amplifies photoacoustic imaging and photothermal effect, rendering great promise for image‐guided cancer immunotherapy. High‐performance theranostic systems are of paramount importance for achieving precise image‐guided cancer immunotherapy. Here, a novel nanoplatform is presented that integrates aggregation‐induced emission luminogen (AIEgen) with prussian blue (PB) nanocatalyzer for robust cancer immunotherapy. The AIEgen with dimethylamine substitution demonstrates compelling near‐infrared (NIR) light‐induced photothermal conversion and photodynamic therapy (PDT) capabilities. By incorporating AIEgen into porous PBNPs, and further enveloped within M1 macrophage membrane, a tumor‐specific theranostic nanoagent is constructed. This strategic integration effectively constrains the molecular motion of AIEgen, leading to amplified NIR‐II fluorescence brightness and PDT attributes. Moreover, PBNPs can catalyze tumor‐overexpressed H2O2 to generate oxygen to boost PDT efficacy, and PB's NIR absorption also intensifies photoacoustic imaging and photothermal effect. The integration of NIR‐II fluorescence and photoacoustic imaging provides comprehensive information for photoimmunotherapy in orthotopic breast cancer‐bearing mice. Leveraging its potent immunogenic cell death effect, the nanoagent not only significantly inhibits cancer growth, but also generates a whole‐cell therapeutic cancer vaccine to protect mice from tumor rechallenge. In highly malignant post‐surgery breast cancer models, the nanoagent enables both accurate identification of residual tumors and efficient inhibition of postoperative tumor recurrence and pulmonary metastasis. This study will offer valuable insights for creating highly efficacious and multifaceted photoimmunotherapy protocols.

Biosynthetic Dendritic Cell-Exocytosed Aggregation-Induced Emission Nanoparticles for Synergistic Photodynamic Immunotherapy

Aggregation‐Induced‐Emission Photosensitizer‐Loaded Nano‐superartificial Dendritic Cells with Directly Presenting Tumor Antigens and Reversed Immunosuppression for Photodynamically Boosted Immunotherapy

A Biomimetic Aggregation‐Induced Emission Photosensitizer with Antigen‐Presenting and Hitchhiking Function for Lipid Droplet Targeted Photodynamic Immunotherapy

Engineered Extracellular Vesicles Expressing Siglec‐10 Camouflaged AIE Photosensitizer to Reprogram Macrophages to Active M1 Phenotype and Present Tumor‐Associated Antigens for Photodynamic Immunotherapy

Antigen‐Capturing Dendritic‐Cell‐Targeting Nanoparticles for Enhanced Tumor Immunotherapy Based on Photothermal‐Therapy‐Induced in‐situ Vaccination

Mature Dendritic Cell-Derived Dendrosomes Swallow Oxaliplatin-Loaded Nanoparticles to Boost Immunogenic Chemotherapy and Tumor Antigen-Specific Immunotherapy

Engineered Extracellular Vesicles to Enhance Antigen Presentation for Boosting Light‐Driven Tumor Immunotherapy

NIR-light triggered dual-cascade targeting core-shell nanoparticles enhanced photodynamic therapy and immunotherapy

Engineering ApoE3-incorporated Biomimetic Nanoparticle for Efficient Vaccine Delivery to Dendritic Cells Via Macropinocytosis to Enhance Cancer Immunotherapy

In Situ Manipulation of Dendritic Cells by an Autophagy-Regulative Nanoactivator Enables Effective Cancer Immunotherapy

Smart Nanovesicle-Mediated Immunogenic Cell Death Through Tumor Microenvironment Modulation for Effective Photodynamic Immunotherapy.

Mitochondria-targeted nano-AIEgens as a powerful inducer for evoking immunogenic cell death

All-in-One Theranostic Platforms: Deep-Red AIE Nanocrystals to Target Dual-Organelles for Efficient Photodynamic Therapy.

Two‐Pronged Intracellular Co‐Delivery of Antigen and Adjuvant for Synergistic Cancer Immunotherapy

Engineering Nanoscale Artificial Antigen-Presenting Cells By Metabolic Dendritic Cell Labeling To Potentiate Cancer Immunotherapy

Cooperative Self-Assembled Nanoparticle Induces Sequential Immunogenic Cell Death and Toll-Like Receptor Activation for Synergistic Chemo-immunotherapy

Boosting Theranostic Performance of AIEgens Using Nanocatalyzer for Robust Cancer Immunotherapy

Protein-assisted Synthesis of Chitosan-Coated Minicells Enhance Dendritic Cell Recruitment for Therapeutic Immunomodulation Within Pulmonary Tumors

Identification of a novel DEC-205 binding peptide to develop dendritic cell-targeting nanovaccine for cancer immunotherapy

Dual‐Activatable Nano‐Immunomodulator for NIR‐II Fluorescence Imaging‐Guided Precision Cancer Photodynamic Immunotherapy

Extracellular matrix-degrading STING nanoagonists for mild NIR-II photothermal-augmented chemodynamic-immunotherapy